ReviewEndocrinology, diabetes & metabolism2026
Type 2 Diabetes From the Perspective of Telomere Biology.
Review in Endocrinology, diabetes & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundType 2 diabetes mellitus (T2DM) has emerged as one of the most critical public health challenges worldwide, with its prevalence continuing to rise steadily. Current projections estimate that the global number of individuals affected by T2DM will reach approximately 783 million by 2045, imposing an increasingly severe burden on healthcare systems globally. In recent years, growing attention has been directed toward the relationship between telomere biology and metabolic disorders. Telomeres, the protective structures at the ends of chromosomes, serve as key markers of cellular aging, with their length and integrity reflecting biological age. Telomerase, a specialised enzyme complex, plays a central role in maintaining telomere stability. Accumulating evidence suggests that telomere shortening and dysfunction not only accelerate organismal aging but may also contribute to the pathogenesis of T2DM through multiple molecular pathways.
objectiveThis review aims to systematically synthesise recent research advances regarding the association between telomeres and T2DM, and to explore the clinical translational potential of telomere length and telomerase activity as biomarkers of disease risk or as potential therapeutic targets.
methodsA systematic search of relevant articles was conducted across databases including PubMed, Web of Science, and CNKI. Search terms comprised 'Telomere', 'Telomerase', 'T2DM' and 'Treatment'. Through screening and integration of evidence from cellular experiments, animal model studies, population-based epidemiological investigations and clinical observational research, this review systematically synthesises the mechanistic evidence and current research landscape regarding the association between telomeres and T2DM.
resultsAccumulating evidence consistently indicates a significant association between telomere biology and the development and progression of T2DM. Key mechanisms primarily involve oxidative stress and cellular apoptosis, while telomere dysfunction may also contribute to glucose metabolism disorders by impairing pancreatic β-cell function and peripheral tissue insulin sensitivity. Dynamic changes in telomeres hold promise as novel biomarkers for assessing T2DM risk and disease progression.
conclusionsA close and bidirectional relationship exists between telomere biology and T2DM. Deeper insights into this association not only enhance our understanding of T2DM pathogenesis but also offer potential therapeutic targets for anti-aging-based interventions, highlighting important clinical translation prospects. Future research should further clarify the causal relationships involved and explore strategies aimed at preserving telomeres or modulating telomerase activity to delay diabetes progression and prevent its complications, thereby advancing novel approaches for early risk assessment and precision management of T2DM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.